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1501to Assess Improvement in Therapeutic Outcomes by
Optimizing Platelet Inhibition with Prasugrel–Thrombol-
ysis In Myocardial Infarction 38) trial (9) and the PLATO
(Platelet Inhibition and Patient Outcomes) trial (10) of
prasugrel and ticagrelor, respectively, have shown them to be
superior to clopidogrel in reducing thrombotic events. On
the basis of these results, prasugrel was approved to reduce
the rate of thrombotic cardiovascular events in patients with
ACS who are to be managed with percutaneous coronary
intervention (PCI), and ticagrelor was approved for the
prevention of atherothrombotic events in all patients with
ACS (1–3). Prasugrel is a prodrug with an active metabolite
that binds irreversibly to the P2Y12 receptor and is dosed
once daily (QD) (11), whereas ticagrelor binds reversibly to
the P2Y12 receptor and has a twice-daily (BID) dosing
regimen (12).
In certain clinical situations, switching from ticagrelor
to prasugrel therapy may be considered; for example, in
patients experiencing dyspnea or because QD adminis-
tration might improve compliance. However, the phar-
macodynamic effects of switching from ticagrelor to
prasugrel are unknown. It has been reported that ticagrelor
binds to a site on the P2Y12 receptor distinct from
the adenosine diphosphate–binding site. However, it is
unknown whether ticagrelor, or its active metabolite (AR
C124910XX), interferes with the binding of the prasugrel-
active metabolite to P2Y12, which has a short half-life in
plasma (approximately 7 h) (11), leading to a pharmaco-
dynamic interaction induced by competition for the bind-
ing site.
The objective of the present study was to compare the
pharmacodynamic effects of switching from ticagrelor to
prasugrel therapy in patients with stable coronary artery
disease (CAD).
Methods
Study design. SWAP-2 (Switching Anti Platelet–2) was
a Phase IV, randomized, multicenter, open-label (blinded
pharmacodynamic results), 3-arm, parallel-design study
(Fig. 1). The study consisted of a run-in phase in which
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Manuscript received October 28, 2013; revised manuscript received November 15,
2013, accepted November 26, 2013.(LD) and then a ticagrelor 90-mg
BID maintenance dose (MD) for
3 to 5 days. After the 3- to 5-day
ticagrelor run-in phase, patients
were randomized (1:1:1) to receive
1 of the following 3 regimens: 1)
prasugrel 60-mg LD followed by
prasugrel 10-mg QD MD; 2)
prasugrel 10-mg QD MD; or 3)
continuation on ticagrelor 90-mg
BID MD for 7 days.
All subjects provided written
informed consent before partici-
pation in the study. The SWAP-2
study was conducted in com-
pliance with the principles of
the Declaration of Helsinki and
the International Conference on
Harmonisation consolidated guide-
lines. It was approved by the in-
stitutional review board of each
study site (Online Appendix).
Patients. Patients aged 18 to 75
years and weighing 60 kg with
stable CAD and on low-dose aspirin therapy (75- to
150-mg daily) for 7 days before screening were eligible for
enrollment. Stable CAD was deﬁned as any of the following:
1) history of a positive result on stress testing; 2) previous
coronary revascularization; 3) angiographic demonstration
of CAD (1 lesion with 50% stenosis); 4) presence of at
least moderate plaque according to computed tomography
angiography; or 5) electron beam computed tomography
coronary artery calciﬁcation score 100 Agatston units.
Female subjects of childbearing potential were required to
practice at least 1 form of birth control (excluding partner’s
use of condoms or partner’s vasectomy). Subjects were
excluded if they had a deﬁned recommendation for P2Y12
receptor antagonist therapy such as being within 12 months
of an ACS diagnosis or PCI (1–3). Prohibited medications
included antiplatelet agents other than aspirin, warfarin,
nonsteroidal anti-inﬂammatory drugs, or cyclooxygenase-2
inhibitors (exceeding 3 doses per week), strong inhibitors/
inducers of cytochrome P450 3A4, and higher doses of
simvastatin or lovastatin (>40 mg/day). Full inclusion and
exclusion criteria are included in the Online Appendix.
Assessment of platelet function. Blood samples were
collected for platelet function testing at 7 time points: before
the ticagrelor LD (pre–run-in baseline), immediately before
the ﬁrst dose of randomized drug (pre-randomization
baseline), and at 2, 4, 24, and 48 h and 7 days after the ﬁrst
dose of randomized treatment (Fig. 1). Samples were pro-
cessed within 1 h by operators who were blinded to treat-
ment. The VerifyNow P2Y12 assay (Accumetrics, Inc., San
Diego, California), reported as P2Y12 reaction units (PRU),
and the vasodilator-stimulated phosphoprotein phosphory-
lation assay (Biocytex, Inc., Marseille, France), expressed as
Figure 1 Study Design
Platelet reactivity was assessed at 7 time points: pre–run-in baseline, pre-
randomization baseline, and at 2, 4, 24, and 48 h and 7 days after the ﬁrst dose of
randomized treatment. CAD ¼ coronary artery disease; LD ¼ loading dose; MD ¼
maintenance dose.
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viously described (13).
High on-treatment platelet reactivity (HPR) was evalu-
ated at 2, 4, 24, and 48 h and at 7 days by using 3 deﬁni-
tions: 1) 208 PRU; 2) 230 PRU; and 3) PRI >50%.
These cutoff points have been shown to correlate with
cardiovascular endpoints, as summarized in an updated
consensus statement (7).
Study endpoints and statistical analysis. The primary
hypothesis was that after 7 days of randomized treatment,
PRU as assessed by using the VerifyNow P2Y12 assay would
be noninferior in patients switched from ticagrelor to pra-
sugrel compared with patients remaining on ticagrelor; 45
PRU was used as the noninferiority margin for the upper
95% conﬁdence interval (CI) limit of the difference. Least-
squares (LS) mean differences in PRU between the com-
bined prasugrel groups and the ticagrelor group (prasugrel
PRU – ticagrelor PRU) and the corresponding 2-sided 95%
CIs for the difference were obtained based on an analysis of
covariance (ANCOVA) model, with treatment as the main
effect and PRU at pre-randomization baseline as a covariate.
Secondary endpoints included comparisons between the
combined prasugrel groups and the ticagrelor group for
PRU at other time points and the PRU calculated and
device-reported percent inhibition and PRI for all post-
randomization time points. For all comparisons, 2-sided
95% CIs for the mean differences were constructed by us-
ing an ANCOVA model, with treatment as main effect and
pre-randomization baseline value as a covariate. Percentages
of patients with HPR were summarized according to
treatment arm after 2, 4, 24, and 48 h and 7 days of ran-
domized treatment. Safety endpoints included a collection ofadverse events, including bleeding events, clinical laboratory
parameters, vital signs, and physical examinations, and are
presented with a descriptive analysis because the trial was not
sized to adequately evaluate clinical endpoints. At each visit,
drug compliance was performed by tablet counts of each
returned study medication.
The sample size was based on the objective of establishing
noninferiority of prasugrel 10-mg QD MD (based on com-
bined prasugrel-treated patients) compared with ticagrelor
90-mg BID MD with respect to PRU. Assuming a zero
difference in mean PRU between treatment groups, a
common SD of 60 PRU (14,15), and a dropout rate not
exceeding 15%, a sample size of 105 allows for the 95% CI
of the treatment difference to stay within 45 PRU with a
probability of 0.90. The use of a PRU value of 45 as the
upper limit of the CI was an arbitrary choice based on a
consensus of the investigators, with the assumption that
any PRU difference <45 would not result in a meaningful
difference in clinical effect.
The primary population included all patients who
received 1 dose of randomized study drug, did not take
certain prohibited concomitant medications at screening
and during the study (Online Appendix), and had valid
PRU data at both randomization visits pre-dosing and end-
of-treatment visit. The primary population was used for
analysis of primary and secondary pharmacodynamic end-
points. The treated population included all patients who
received 1 dose of randomized study medication and
was used for analysis of safety endpoints.
Subgroup analyses of the primary endpoint were per-
formed for sex, diabetic status, and body mass index (BMI)
categories. A sensitivity analysis was also conducted to
identify and adjust for any signiﬁcant covariates by using
the ANCOVA model and a backward selection procedure
with signiﬁcance level of 0.10. Comparisons of baseline
characteristics between the combined prasugrel groups and
the ticagrelor group used analysis of variance for continuous
variables and the Fisher exact test for proportions. Within-
group comparisons of pharmacodynamic variables between
post-treatment time points and baseline were made ac-
cording to paired Student t tests. No adjustment for multiple
comparisons was performed.Results
Subjects. Subject disposition is summarized in Figure 2. A
total of 120 patients entered the run-in phase of the
study; of these, 110 were randomized to treatment (treated
population), and 98 met the criteria for inclusion in the
primary population. Four patients randomized to the pra-
sugrel 60-mg LD plus 10-mg MD group inadvertently
only received the MD of prasugrel on randomization; they
were therefore included in the prasugrel MD group for
analyses. Demographic and baseline characteristics were
similar between groups, with the exception that patients in
the prasugrel groups were heavier and more likely to have
Figure 2 Subject Disposition
After a 3- to 5-day run-in period with a ticagrelor 180-mg LD/90-mg twice-daily MD, patients were randomized to 1 of the following treatment arms in a 1:1:1 ratio: prasugrel
10-mg LD, followed by prasugrel 10-mg once-daily; prasugrel 10-mg once-daily MD; or ticagrelor 90-mg twice-daily MD. Of the 110 patients who were randomized to treatment,
106 completed the study. *Treated population. y4 subjects randomized to the prasugrel 60-mg LD/10-mg MD group inadvertently only received MD and were included in the
prasugrel 10-mg MD group for analyses. PRU ¼ P2Y12 reaction unit.
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1503diabetes (Table 1). Subgroup analyses according to diabetic
status and BMI category found that treatment differences
were similar between subgroups. In addition, sensitivity
analysis using ANCOVA showed that neither diabetic sta-
tus nor weight or BMI was a signiﬁcant factor for PRU
at 7 days. Compliance to study medication was high in
all treatment groups. Overall compliance was 98.6% in the
combined prasugrel group and 98.8% in the ticagrelor group.
Pharmacodynamic results. At 7 days’ post-randomization,
PRU was signiﬁcantly higher in the combined prasugrel
groups compared with those receiving ticagrelor, with mean
 SD values of 95.6  54.12 and 47.9  47.59, respectively.The LS mean difference between treatment groups was 46
(95% CI: 24.9 to 67.2; p < 0.001), and the upper 95% CI
limit exceeded 45 PRU and thus did not reach the non-
inferiority objective (primary endpoint) (Table 2). An
analysis of PRU over time revealed that PRU increased at
24 and 48 h in both prasugrel groups relative to pre-
randomization values, with the smaller increase among
those receiving prasugrel with an LD compared with
those receiving only an MD (Fig. 3). In the prasugrel
MD group, the PRU increased from 47.40  36.01 at
pre-randomization to 168.2  67.97 (p < 0.001 for change
from pre-randomization baseline) at 24 h and to 198.3 
Table 1 Baseline Demographic Characteristics (Primary Population)
Treatment Group
Ticagrelor
(n ¼ 33) p Value
Prasugrel 60-mg LD þ 10-mg MD
(n ¼ 31)
Prasugrel 10-mg MD
(n ¼ 34)
Prasugrel Total
(n ¼ 65)
Country >0.999
United States 29 (93.5) 31 (91.2) 60 (92.3) 30 (90.9)
Great Britain 2 (6.5) 3 (8.8) 5 (7.7) 3 (9.1)
Age (yrs) 57.5  10.1 58.9  8.5 58.2  9.3 61.8  7.0 0.057
Sex 0.641
Male 22 (71.0) 24 (70.6) 46 (70.8) 25 (75.8)
Female 9 (29.0) 10 (29.4) 19 (29.2) 8 (24.2)
Weight (kg) 96.9  18.0 95.1  19.0 96.0  18.4 88.3  18.0 0.054
BMI (kg/m2)
Mean  SD 32.9  6.0 32.5  6.1 32.7  6.0 29.2  4.7 0.004
<30 kg/m2 13 (41.9) 13 (38.2) 26 (40.0) 23 (69.7) 0.01
30 kg/m2 18 (58.1) 21 (61.8) 39 (60.0) 10 (30.3) 0.01
Medical history
Diabetes 14 (45.2) 11 (32.4) 26 (38.5) 5 (15.2) 0.021
Hypertension 24 (77.4) 25 (73.5) 49 (75.4) 22 (66.7) 0.473
Hyperlipidemia 30 (96.8) 29 (85.3) 59 (90.8) 29 (87.9) 0.729
Peripheral arterial disease 2 (6.5) 1 (2.9) 3 (4.6) 2 (6.1) >0.999
Values are n (%) or mean  SD.
BMI ¼ body mass index; LD ¼ loading dose; MD ¼ maintenance dose.
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150461.85 (p < 0.001 for change from pre-randomization
baseline) at 48 h. The corresponding values for the prasu-
grel LD group were 50.3  41.70, 83.4  63.97 (p ¼ 0.002
for change from pre-randomization baseline), and 120.2 
71.33 (p < 0.001 for change from pre-randomization
baseline). The difference between the prasugrel MD group
and the prasugrel LD group was statistically signiﬁcant at
24 and 48 h (p < 0.001 for both). Calculated and device-
reported percent inhibition with the VerifyNow assays
agreed with these results (data not shown).
Similar results were observed for PRI (Table 2). At 7 days,
PRI in the primary population was signiﬁcantly higher in the
combined prasugrel group, with mean values of 32.4 
18.57% compared with 20.1  17.83% for the ticagrelor
group. The LS mean difference between the combined pra-
sugrel and ticagrelor groups was 13.6% (95% CI 4.6 to 22.6;
p¼ 0.004).Aswas seenwith PRU, PRI increased at 24 and 48
h in both prasugrel groups relative to pre-randomization
values, with the smaller increase among those receiving pra-
sugrel with an LD compared with those receiving only an
MD. In the prasugrel MD group, the mean PRI increased
from 18.8 17.63% at pre-randomization to 44.3 18.28%
(p < 0.001 for change from baseline) at 24 h and to 58.8 
17.57% (p < 0.001 for change from baseline) at 48 h. The
corresponding values for the prasugrel LD group were 17.8
14.19%, 23.0 13.75% (p¼ 0.055 for change from baseline),
and 37.3  17.10% (p < 0.001 for change from baseline).
The difference between the prasugrel MD group and the
prasugrel LD group was statistically signiﬁcant at 24 and 48 h
(p < 0.001 for both).
Rates of HPR at 7 days were similar between the com-
bined prasugrel groups and ticagrelor group based on PRUcutoff points of 208 (1.5% vs. 3.0%; p > 0.999) or 230
(1.5% vs. 3.0%; p > 0.999). HPR frequency was nonsig-
niﬁcantly higher for prasugrel using the PRI >50% cutoff
point at 7 days (15.5% vs. 3.4%; p ¼ 0.155) (Fig. 4). At the
24- and 48-h time points, the prasugrel MD group had
signiﬁcantly higher rates of HPR than ticagrelor for all
HPR criteria; the prasugrel LD plus MD group had non-
signiﬁcantly higher rates of HPR than the ticagrelor group
for all HPR criteria, except for PRU 208 at 48 h. Sig-
niﬁcant differences between the 2 prasugrel groups were
observed, with rates of HPR being lower at 24 h using
PRU 208 (3.3% vs. 30.3%; p ¼ 0.007), PRU 230 (3.3%
vs. 24.2%; p ¼ 0.028), and PRI >50% (3.4% vs. 37.5%;
p ¼ 0.001) for patients in the prasugrel LD plus MD
group compared with those receiving prasugrel MD only.
Similarly, rates of HPR were also signiﬁcantly lower for
those receiving prasugrel LD only compared with those
receiving prasugrel MD only at the 48-h time point using
PRU 208 (16.1% vs. 43.8%; p ¼ 0.027), PRU 230
(6.5% vs. 37.5%; p ¼ 0.005), and PRI >50% (13.8% vs
74.2%; p < 0.001).
Safety. Adverse event data are summarized in Online
Table 1. The overall rates of any treatment-emergent
adverse event (post-randomization) and any treatment-
related adverse event were 34% versus 24% (ticagrelor
versus prasugrel) and 23% versus 13%, respectively. Hem-
orrhagic treatment-emergent adverse events (primarily mild
ecchymosis) tended to be higher in the ticagrelor group
compared with the combined prasugrel groups (20% vs.
11%). One subject randomized to receive ticagrelor experi-
enced dyspnea, and an additional 4 subjects reported dys-
pnea during the ticagrelor run-in phase and were not
Table 2 Measures of Platelet Reactivity (Primary Population)
Prasugrel
Ticagrelor
90 mg BID
(n ¼ 33)
Prasugrel LD Group;
LS Mean Difference*
(95% CI; p Value)
Prasugrel MD Group;
LS Mean Differencey
(95% CI; p Value)
Prasugrel Combined Group;
LS Mean Differencez
(95% CI; p Value)
60-mg LD þ 10 mg QD
(n ¼ 31)
10 mg QD
(n ¼ 34)
Combined
(n ¼ 65)
P2Y12 assay,x PRU
Pre–run-in baseline 274.5  39.86 271.1  41.88 272.7  40.66 260.0  43.10
Pre-randomization
baseline
50.3  41.70 47.4  36.01 48.8  38.55 44.7  41.30
2 h 24.0  24.18 46.1  38.93 35.2  34.14 25.7  20.75 6.8 (18.7 to 5.1; p ¼ 0.261) 15.9 (4.1 to 27.7; p ¼ 0.009) 4.8 (6.3 to 15.8; p ¼ 0.395)
4 h 25.2  20.06 57.2  41.34 41.7  36.34 28.1  26.49 5.1 (18.1 to 7.8; p ¼ 0.433) 27.7 (14.9 to 40.4; p < 0.001) 11.8 (0.7 to 24.3; p ¼ 0.063)
24 h 83.4  63.97 168.2  67.97 127.8  78.24 45.4  31.85 33.9 (9.2 to 58.7; p ¼ 0.008) 120.2 (96.0 to 144.3; p < 0.001) 79.2 (53.0 to 105.4; p < 0.001)
48 h 120.2  71.33 198.3  61.85 159.8  76.97 37.6  27.46 79.7 (54.0 to 105.4; p < 0.001) 160.4 (134.9 to 185.9; p < 0.001) 120.8 (94.5 to 147.1; p < 0.001)
7 days 98.7  61.15 92.7  47.56 95.6  54.12 47.9  47.59 48.6 (23.7 to 73.5; p < 0.001) 43.7 (19.4 to 68.0; p < 0.001) 46.0 (24.9 to 67.2; p < 0.001)
VASP, PRI
Pre–run-in baseline 83.9  7.10 86.6  4.64 85.3  5.99 85.4  4.27
Pre-randomization
baseline
17.8  14.19 18.8  17.63 18.4  15.93 23.4  18.67
2 h 13.7  12.27 19.5  19.24 16.7  16.32 15.4  13.57 2.6 (–2.8 to 8.0; p ¼ 0.338) 7.2 (2.0 to 12.5; p ¼ 0.007) 5.0 (0.39 to 9.64; p ¼ 0.034)
4 h 10.1  8.77 20.3  18.30 15.3  15.19 15.7  11.02 2.9 (8.9 to 3.1; p ¼ 0.334) 6.6 (0.8 to 12.4; p ¼ 0.027) 2.0 (3.3 to 7.4; p ¼ 0.452)
24 h 23.0  13.75 44.3  18.28 34.2  19.38 20.1  14.92 5.0 (–2.8 to 12.9; p ¼ 0.205) 24.5 (16.8 to 32.2; p < 0.001) 15.2 (7.6 to 22.8; p < 0.001)
48 h 37.3  17.10 58.8  17.57 48.4  20.33 19.7  18.15 19.4 (10.1 to 28.6; p < 0.001) 39.0 (29.9 to 48.2; p < 0.001) 29.5 (20.8 to 38.2; p < 0.001)
7 days 35.6  22.22 29.8  14.83 32.4  18.57 20.1  17.83 19.0 (8.4 to 29.5; p < 0.001) 9.3 (–0.8 to 19.3; p ¼ 0.069) 13.6 (4.6 to 22.6; p ¼ 0.004)
Values are mean  SD unless otherwise indicated. *Prasugrel 60-mg LD þ 10-mg MD versus ticagrelor. yPrasugrel 10-mg MD versus ticagrelor. zPrasugrel combined versus ticagrelor. xVerifyNow P2Y12 assay (Accumetrics, Inc., San Diego, California).
BID ¼ twice-daily; CI ¼ conﬁdence interval; LS ¼ least-squares; PRI ¼ platelet reactivity index; PRU ¼ P2Y12 reaction unit; QD ¼ once-daily; VASP ¼ vasodilator-stimulated phosphoprotein; other abbreviations as in Table 1.
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Figure 3 Platelet Reactivity Over Time
At 24 and 48 h, PRU increased in both prasugrel (Pras) groups relative to pre-randomization values, with a smaller increase among those patients receiving Pras with an LD
compared with those receiving only an MD. Rand. ¼ randomized to treatment; Ticag ¼ ticagrelor; other abbreviations as in Figures 1 and 2.
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1506randomized to treatment. There were no deaths in any
treatment group.
Discussion
Prasugrel and ticagrelor are new P2Y12 inhibitors that
provide greater and faster platelet inhibition with less
interindividual variability compared with clopidogrel
(13,16–19). In the case of prasugrel, these effects are due to
differences in pharmacokinetics (16) and may explain the
greater efﬁcacy of prasugrel compared with clopidogrel
in reducing thrombotic cardiovascular events in patients
with ACS receiving PCI, albeit at the expense of an
increased risk of bleeding (9). In PLATO, ticagrelor was
associated with a reduction in cardiovascular events, in-
cluding death from vascular causes, compared with clopi-
dogrel in patients with ACS, with no differences in overall
bleeding but with an increased risk of spontaneous major
bleeding (10).
Switching from ticagrelor therapy may be considered for
patients who experience adverse effects (particularly dys-
pnea). Although the rate of dyspnea in the current study was
low, higher rates have been reported in other studies (10,19).
Switching such patients to clopidogrel is an option, but
the drug has a number of limitations compared with pra-
sugrel, including variability in platelet inhibitory response
and a lower clinical efﬁcacy in high-risk patients (5,9,14).
Given that prasugrel is administered QD (versus BIDadministration for ticagrelor), physicians may want to switch
patients from ticagrelor to prasugrel for maintenance therapy
to improve compliance. Compliance with dual antiplatelet
therapy is of key importance, particularly in patients treated
with drug-eluting stents, as underscored in recent PCI
guidelines that also include a caveat for use of ticagrelor if
patient compliance is an issue (2).
SWAP-2 is the ﬁrst study designed to evaluate the effect
on platelet reactivity of switching from ticagrelor to prasugrel
therapy. SWAP-2 did not meet its primary objective of
demonstrating noninferiority of prasugrel versus ticagrelor
with respect to PRU after 7 days of study treatment. In
addition, during the early switching phase (i.e., 24- and 48-h
time points), prasugrel was associated with signiﬁcantly
higher platelet reactivity compared with ticagrelor. This
ﬁnding suggests a pharmacodynamic drug interaction be-
tween ticagrelor and prasugrel, particularly in patients not
receiving an LD, in which there was an initial increase in
platelet reactivity followed by a decrease at 7 days. Never-
theless, rates of HPR were low for both prasugrel and
ticagrelor after 7 days of treatment when using the PRU
cutoff points of 208 or 230, although HPR remained
nonsigniﬁcantly higher for prasugrel using the cutoff point
of PRI >50%. In prasugrel-treated patients, a greater pre-
valence of HPR has been shown when using PRI compa-
red with PRU (20); an important observation such as HPR
in prasugrel-treated patients has been associated with an
increased risk of ischemic events (21).
Figure 4 HPR Status Over Time
(A) PRU 208; (B) PRU 230; and (C) platelet reactivity index (PRI) >50% (primary population). At 7 days, rates of high on-treatment platelet reactivity (HPR) were similar
between the combined Pras groups and the Ticag group based on PRU cutoff points of 208 or 230 and were nonsigniﬁcantly higher for Pras using the PRI >50% cutoff point
compared with the Ticag group. *p < 0.05 versus Ticag; yp < 0.01 versus Ticag. Abbreviations as in Figures 1 to 3.
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1507The pattern of platelet inhibition observed in patients
treated with prasugrel after a ticagrelor run-in phase was not
consistent with observations from patients switched from
clopidogrel to prasugrel. In the SWAP study, switching
from maintenance clopidogrel to prasugrel, with or without
an LD, was associated with further platelet inhibition
without an initial increase, as seen in this study (22), and a
lower rate of HPR versus clopidogrel (23). Reasons for these
disparities are unknown but may be related to the switch to
an agent from a different drug class (as in the current study)
versus switching to an agent in the same class (as in the
original SWAP study). Switching from clopidogrel, which
binds irreversibly to the P2Y12 receptor, to prasugrel may
have resulted in an additive antiplatelet effect with the
prasugrel-active metabolite binding to additional P2Y12 re-
ceptors. With ticagrelor, it is possible that a greater number
of P2Y12 receptors are occupied than with clopidogrel,thereby preventing the active metabolite of prasugrel from
binding to the receptor during the immediate switching
phase. The prasugrel-active metabolite may not be able to
bind to the receptor until ticagrelor dissociates. Ticagrelor
may also induce a change in receptor conformation that
precludes prasugrel-active metabolite binding. The latter
could explain the delay in platelet inhibition in the prasugrel
groups in the current study. The potential for a prolonged
receptor interaction is consistent with the observation of a
persistent (at least 72 h) antiplatelet effect with ticagrelor
during the offset phase (19), although some data suggest
that ticagrelor binds to a receptor site different from (and
noncompetitive with) the thienopyridines (12). Moreover,
the pharmacodynamic effects of the active metabolite of
ticagrelor (AR-C124910XX) are not well characterized and
may play a role in the observed pharmacodynamic interac-
tion between prasugrel and ticagrelor. Finally, ticagrelor may
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For example, a recent pharmacodynamic study found that
in patients with HPR, ticagrelor produced signiﬁcantly
higher platelet inhibition than prasugrel, although both
drugs effectively overcame HPR (24). However, although
decreased platelet reactivity is strongly associated with lower
rates of cardiovascular endpoints, it is also associated with
a higher risk of bleeding (5,7).
The observation that patients receiving a prasugrel LD
exhibited more consistent platelet inhibition than those
who only received an MD suggests that an LD is important
when patients are switched to prasugrel. Although our data
do not address the optimal timing of an LD, it may be
hypothesized that waiting a longer duration than that
considered in this study to administer the LD of prasugrel
after the last MD of ticagrelor may allow for more P2Y12
receptors to be unbound by ticagrelor and more susceptible
to the effects of prasugrel. Indeed, further studies are
required to identify the optimal timing of the LD of prasugrel
in the setting of switching from ticagrelor to prasugrel. Also,
although our study ﬁndings suggest a potential pharmacolog-
ical interaction when switching from ticagrelor to prasugrel,
dedicated mechanistic studies are needed to conﬁrm this
hypothesis.
Study limitations. Study limitations of SWAP-2 include
the use of an arbitrary upper limit of the CI for PRU. At
the time of the study development, any difference <45 PRU
was not considered to result in a meaningful clinical difference,
although this value was not based on clinical outcomes data.
Another limitation is that the study was conducted in patients
with stable CAD. These subjects were chosen because pati-
ents with ACS need dual antiplatelet therapy, and it was un-
known if there was an interaction between ticagrelor and
prasugrel, as found in this study, which could have put pati-
ents at risk for an adverse clinical outcome. Thus, it is unclear
whether or how the results of the current study will be appli-
cable to those with ACS. Also, 4 subjects randomized to the
prasugrel 60-mg LD plus 10-mg MD group inadvertently
only received the MD of prasugrel upon randomization and
were included in the prasugrel MD group. In addition, this
pharmacodynamic study was not designed or sized to deter-
mine the effect of switching on the incidence of cardiovascular
thrombotic events or bleeding. Further studies are needed to
better understand the dynamics of the interaction between
prasugrel and ticagrelor on the P2Y12 receptor.
Conclusions
SWAP-2 did not achieve the primary objective of non-
inferiority of pharmacodynamic response after switching
from ticagrelor to prasugrel. The results suggest a pharma-
codynamic interaction when switching from ticagrelor to
prasugrel, which is partially mitigated with administration
of an LD of prasugrel. This interaction resulted in higher
rates of HPR in the ﬁrst 24 to 48 h after switching, which
diminished by 7 days of treatment. The clinical implicationsof our study ﬁndings cannot be extrapolated from the results
of this study and deserve further investigation as to the
optimal timing of switching from ticagrelor to prasugrel.
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